Sionna Therapeutics (SION) risk factors
Item 1A of every Sionna Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks15 new13 dropped19 reworded
Sionna Therapeutics added new disclosures addressing risks related to novel CFTR NBD1 targeting, government shutdowns impacting FDA reviews, and updated tax legislation.
Filed Mar 02, 2026 - FY2024 10-K risk factors67 risks
Sionna Therapeutics faces heavy developmental risks focusing on its novel NBD1 domain cystic fibrosis product candidates, including SION-719 and SION-451. The company relies entirely on early preclinical data and Phase 1 trials conducted in Australia, with no prior clinical trials in cystic fibrosis patients. Operations depend heavily on third-party manufacturers, licensed intellectual property, and competing against established standard-of-care therapy Trikafta.
Filed Mar 20, 2025